[II型5-羟色胺受体拮抗剂萘呋胺酯治疗间歇性跛行患者]
[The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
作者信息
Komarov A L, Panchenko E P, Eshkeeva A R, Dobrovol'skiĭ A B, Titaeva E V, Karpov Iu A
出版信息
Ter Arkh. 1996;68(2):49-53.
PMID:8771659
Abstract
The authors' findings say about compatibility of clinical responses to naftidrofuril (daily dose 600 mg) and pentoxifillin (daily dose 600 mg) in patients with atherosclerosis of the lower limb artery and intermittent claudication stage II. Both the drugs had minimal effects on coagulant and fibrinolytic systems and platelet aggregation.
摘要
作者的研究结果表明，在下肢动脉硬化且处于间歇性跛行II期的患者中，萘呋胺酯（每日剂量600毫克）与己酮可可碱（每日剂量600毫克）的临床反应兼容性如何。两种药物对凝血和纤溶系统以及血小板聚集的影响均微乎其微。
Zotero 插件